List of Figures:
Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012
Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012
Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%)
Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking
Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%)
Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007
Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F
Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007
Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F
Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F
Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008
Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F
Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F
Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F
Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006
Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006
Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006
Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006
Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches
List of Tables:
Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI
Table 3-1: US - Liposuction Statistics (2007)
Table 4-1: Alli - Success & Risk Factor Analysis
Table 4-2: Xenical - Success & Risk Factor Analysis
Table 4-3: Acomplia - Success & Risk Factor Analysis
Table 4-4: Meridia - Success & Risk Factor Analysis
Table 4-5: Obesity Drugs in Phase-III Clinical Trials
Table 4-6: Obesity Drugs in Phase-II Clinical Trials
Table 4-7: Obesity Drugs in Phase-I Clinical Trials
Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F)
Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs
Table 9-1: Abbott Laboratories - Strengths & Weaknesses
Table 9-2: Roche Holding Ltd - Strengths & Weaknesses
Table 9-3: Sanofi-Aventis - Strengths & Weaknesses
Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses
Table 9-5: Pfizer Inc. - Strengths & Weaknesses
